Browse > Article
http://dx.doi.org/10.3857/roj.2016.01732

Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer  

Mattes, Malcolm D. (Department of Radiation Oncology, West Virginia University School of Medicine)
Cardinal, Jon S. (Department of Surgery, West Virginia University School of Medicine)
Jacobson, Geraldine M. (Department of Radiation Oncology, West Virginia University School of Medicine)
Publication Information
Radiation Oncology Journal / v.34, no.2, 2016 , pp. 156-159 More about this Journal
Abstract
Although carbohydrate antigen (CA) 19-9 is a useful tumor marker for pancreatic cancer, it can also become elevated from a variety of benign and malignant conditions. Herein we describe an unusual presentation of elevated CA 19-9 in an asymptomatic patient who had previously undergone adjuvant chemotherapy and radiation therapy for resected early stage pancreatic cancer. The rise in CA 19-9 might be due to delayed radiation-induced inflammation related to previous intra-abdominal radiation therapy with or without radiation recall induced by gemcitabine. After treatment with corticosteroids the CA 19-9 level decreased to normal, and the patient has not developed any evidence of recurrent cancer to date.
Keywords
Pancreatic cancer; Biologic tumor marker; Radiation therapy; Radiation recall reaction; CA 19-9 antigen;
Citations & Related Records
연도 인용수 순위
  • Reference
1 O'Regan KN, Nishino M, Armand P, Kelly PJ, Hwang DG, Di Salvo D. Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med 2010;29:1499-502.   DOI
2 Matthews RH, Kadoch C, Ercal N. Alcohol as a potential contributing factor in radiation complications. Clin Adv Hematol Oncol 2009;7:257-62.
3 Reed GB Jr, Cox AJ Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol. 1966;48:597-611.
4 Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.   DOI
5 Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990;85:350-5.
6 Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9.   DOI
7 Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 1994;35:707-8.   DOI
8 Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10-9.   DOI
9 National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda, MD: National Cancer Institute; c2016 [cited 2016 Jun 7]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
10 Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.   DOI
11 Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998;35(Pt 1):99-103.   DOI
12 Pines E, Slama JL, Holeman A, Ley G, Malbec D, Boudon P. Unusually high level of CA 19-9 in chronic pancreatitis. Gastroenterol Clin Biol 1995;19:641-2.
13 Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91.
14 Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients: relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
15 Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007;21:103-6.   DOI
16 Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45.   DOI
17 Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70.   DOI
18 Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004;100:1793-9.   DOI
19 Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400.   DOI
20 Ganem G, Solal-Celigny P, Joffroy A, Tassy D, Delpon A, Dupuis O. Radiation myositis: the possible role of gemcitabine. Ann Oncol 2000;11:1615-6.   DOI